SCHEMBL6006460

SCHEMBL6006460

CC(NC=O)NS(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
HCRTR1 O43613 1/20 0.47
F2 P00734 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
CASP1 P29466 1/20 0.43
HDAC1 Q13547 1/20 0.42
EDNRB P24530 2/20 0.42
EDNRA P25101 2/20 0.42
ADAM17 P78536 1/20 0.42
SCN1A P35498 2/20 0.42
SCN2A Q99250 2/20 0.42
SCN3A Q9NY46 2/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12132457 0.81 KDM4E (0.56) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL6006410 0.80 SLC1A3 (0.55) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL6006448 0.79 SLC1A3 (0.49) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL13951132 0.78 SLC1A3 (0.54) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL6006417 0.78 SLC1A3 (0.61) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL208173 0.76 CA1 (0.53) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL20025843 0.76 SLC1A3 (0.55) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL29141913 0.75 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1HCRTR1F2
SCHEMBL6006454 0.74 ALDH1A1 (0.53) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL6756547 0.72 SLC1A3 (0.58) SLC1A3SLC1A2SLC1A1HCRTR1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 SLC1A3 2390/4885SLC1A2 2008/4885SLC1A1 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.